ClinicalTrials.gg
RecruitingNCT07370116Updated Nov 18, 2026

Omitting Nasogastric Tube Decompression in Minimally Invasive Pancreaticoduodenectomy

An interventional study of nasogastric tube decompression and Omission of nasogastric tube decompression in Pancreaticoduodenectomy, Nasogastric Tube Decompression and Minimally Invasive Surgical Procedures, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study will evaluate two perioperative nasogastric tube strategies in patients undergoing laparoscopic pancreatoduodenectomy. The goal is to determine whether routine omission of a nasogastric tube is not worse than routine nasogastric tube placement in terms of overall complications and postoperative recovery.

Participants will be randomly assigned to one of two groups. Each group will receive the assigned nasogastric tube strategy during and after surgery, and will be followed during the hospital stay and after discharge for up to postoperative 90 days. Information will be collected from routine clinical care, including discomfort score, symptoms, imaging or laboratory tests when clinically indicated, and postoperative outcomes.

The main outcome of this study is the overall burden of postoperative complications within 30 days after surgery, measured using the Comprehensive Complication Index, which summarizes all complications into a single score. Secondary outcomes include rates of pancreas surgery-specific complications (such as delayed gastric emptying, pancreatic fistula, bile leak, bleeding, and chyle leak), other abdominal and pulmonary complications, and organ dysfunction (including kidney injury, sepsis, and new cardiac dysfunction). The study will also evaluate patient discomfort related to the nasogastric tube (pain/discomfort scores), the need for nasogastric tube reinsertion, postoperative recovery milestones (ability to resume oral intake and length of hospital stay), healthcare costs, and all-cause mortality at 30 and 90 days after surgery.

02

Conditions studied

  • Pancreaticoduodenectomy
  • Nasogastric Tube Decompression
  • Minimally Invasive Surgical Procedures
03

In context

Lead sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences is the lead sponsor of 396 studies on the registry; 281 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 years and 75 years.
  2. Indication for MIPD confirmed by MDT evaluation.
  3. Ability to understand trial requirements and willingness to adhere to study protocols.
  4. Written obtained before registration.
  5. Curative-intent treatment consistent with international clinical guidelines.

Exclusion criteria

Exclusion Criteria:

  1. Requirement of partial or total pancreatectomy or other palliative procedures, or presence of distant (peritoneal, hepatic, distant nodal, or other organ involvement); therefore, these patients are not candidates for MIPD.
  2. American Society of Anaesthesiologists (ASA) Physical Status ≥ IV.
  3. Pregnant or breastfeeding women.
  4. Severe psychiatric disorders.
  5. History of other .
  6. chemoradiotherapy prior to surgery.
  7. >35 kg/m2.
  8. History of nasopharyngeal, gastric or oesophageal surgery.
  9. Preoperative gastrointestinal obstruction.
  10. to nasogastric intubation, including recent caustic ingestion, oesophageal stricture/diverticulum, or maxillofacial trauma.
  11. Participation in any other clinical trials within 3 months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    routine nasogastric tube

    standard nasogastric tube placement with the tube retained postoperatively

    Procedure: nasogastric tube decompression

  • Experimental
    routine omission of the nasogastric tube

    avoidance of prophylactic nasogastric tube placement

    Procedure: Omission of nasogastric tube decompression

Interventions

  • Procedurenasogastric tube decompression

    Nasogastric tube decompression means standard NGT placement with the tube retained postoperatively until the drainage volume is \<500 ml/day on postoperative day 3. Nasogastric tube placement will adhere to the following requirements: pre-insertion nasal patency assessment excluding the side with septal deviation or polyps, catheter pre-measurement from the apex nasi to the ear lobe and xiphoid process, and lubrication with liquid paraffin. After advancement into the pharynx, conscious patients will undergo repeated swallowing to facilitate passage, whereas unconscious patients will require laryngeal elevation with neck flexion to prevent tracheal intubation.

  • ProcedureOmission of nasogastric tube decompression

    Omission of nasogastric tube decompression means avoidance of prophylactic NGT placement throughout the perioperative period. If intraoperative NGT insertion becomes necessary because of acute gastric dilatation, the tube should be removed before anesthesia emergence.

06

What researchers measure

Primary outcomes

  1. Comprehensive Complication Index

    Comprehensive Complication Index calculates a weighted sum of complications graded by the Clavien-Dindo classification that occur within 30 days postoperatively to generate a continuous score from 0 (no complications) to 100 (death), quantifying the overall postoperative complication burden

    Time frame: 30 days postoperatively

Secondary outcomes

  1. pancreaticoduodenectomy-specific complications

    incidence of pancreaticoduodenectomy-specific complications, defined and classified according to International Study Group of Pancreatic Surgery criteria: delayed gastric emptying, postoperative pancreatic fistula, postoperative bile leak, postpancreatectomy haemorrhage, chyle leak and major complications (Clavien-Dindo grade ≥ II)

    Time frame: 30 days postoperatively

  2. abdominal complications

    incidence of abdominal complications: surgical-site infection, intra-abdominal abscess, paralytic ileus, gastric dilatation and gastroenteric anastomotic leak

    Time frame: 30 days postoperatively

  3. pulmonary complications

    incidence of pulmonary complications, including pneumonia, pulmonary embolism, atelectasis and pleural effusion

    Time frame: 30 days postoperatively

  4. comfort

    nasogastric-tube-related discomfort scores (10-cm visual analogue scale)

    Time frame: 30 days postoperatively

  5. Time to tolerate oral intake (liquids/solids)

    Time from the end of surgery to the first time the participant begins and tolerates liquid (and separately solid) oral intake

    Time frame: Up to 90 days postoperatively

  6. Hospitalization cost

    Total hospitalization costs

    Time frame: 90 days postoperatively

  7. Mortality rate

    all-cause mortality rate at postoperative 90 days

    Time frame: 90 days posoperatively

  8. Rescue nasogastric tube insertion

    Postoperative placement (or reinsertion) of a nasogastric tube due to persistent distension, nausea, or vomiting, or if imaging was suggestive of gastrointestinal obstruction.

    Time frame: 90 days postoperatively

  9. Length of stay

    Days from the date of surgery to the date of discharge

    Time frame: Up to 90 days postoperatively

07

Study locations

1 of 1 sites recruiting
  • National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual participant data (IPD) underlying the results reported in publications, along with the data dictionary, will be made available.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Beginning 6 months after publication of the primary results and ending 5 years thereafter.

Access criteria: Researchers who provide a methodologically sound proposal may request access. Proposals will be reviewed by the study team. Access will be provided after execution of a data use agreement. Data will be accessed via a secure platform or institutional controlled-access repository.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2026 (actual). Primary completion is estimated for Mar 2027, 4 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Apr 2026 → Nov 2026, primary completion Jul 2026 → Mar 2027 and completion Sep 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2026
First posted
Jan 27, 2026
StartActual
Nov 1, 2026was Apr 2026
Primary completionEst.
Mar 31, 2027was Jul 2026
CompletionEst.
Jun 30, 2027was Sep 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College is now Recruiting
Nov 18, 2026
Start date
Apr 1, 2026→Nov 1, 2026 (actual)
Nov 18, 2026
Primary completion
Jul 30, 2026→Mar 31, 2027
Nov 18, 2026
Study completion
Sep 2026→Jun 30, 2027
Nov 18, 2026
Sponsor
Collaborators added: Second Affiliated Hospital of Army Medical University; collaborators removed: The Second Affiliated Hospital of the Army Medical University
Nov 18, 2026
Design
Phase 2→Not applicable
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College is now Recruiting
    Start date Apr 1, 2026→Nov 1, 2026 (now actual)
    Primary completion Jul 30, 2026→Mar 31, 2027
    Study completion Sep 2026→Jun 30, 2027
    Sponsor Collaborators added: Second Affiliated Hospital of Army Medical University; collaborators removed: The Second Affiliated Hospital of the Army Medical University
    Design Phase 2→Not applicable
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07370116
Collaborators
Zhejiang Provincial People's Hospital, Shanghai Cancer Centre, The Second Hospital of Hebei Medical University, People's Hospital of Chongqing, Shanghai Zhongshan Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shandong Provincial Hospital, Second Affiliated Hospital of Army Medical University, West China Hospital, Shanxi Province Cancer Hospital
Responsible party
Min Wang (Professor; Chief Physician, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Jan 27, 2026
Start date
Nov 1, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Junzhe Zhuo
Contact
jz.zhuo@outlook.com
+86 18250336385
Min Wang
principal investigator · Department of Pancreatic and Gastric Surgery, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion